Form 4: OptiNose Director Kyle Dempsey Acquires 75,000 Stock Options
SEC Form 4 Filing
Director Kyle Dempsey of OptiNose, Inc. reports the acquisition of 75,000 stock options with an exercise price of $1.04.
Summary
- Kyle Dempsey, a director of OptiNose, Inc., filed a Form 4 disclosing a transaction involving derivative securities.
- On June 6, 2024, Dempsey acquired 75,000 stock options with an exercise price of $1.04.
- The options vest and become exercisable on the earlier of June 6, 2025, or the Issuer's 2025 annual meeting of stockholders, contingent upon continued service with the Issuer.
- Following the reported transaction, Dempsey beneficially owns 75,000 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders, allowing investors to monitor their investment decisions.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: acquisition of stock options. |
| 06/06/2025 | Earliest vesting date for the stock options (one-year anniversary of grant date). |
| 06/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.